Core Insights - United Therapeutics (NASDAQ: UTHR) experienced a surge of over 12% in pre-market trading on March 30, driven by positive TETON-1 trial data, leading to price target increases from BofA and Wells Fargo [2][4] - The trial results indicate a significant expansion of Tyvaso's market potential, moving beyond pulmonary arterial hypertension (PAH) to idiopathic pulmonary fibrosis (IPF), which has a considerable unmet medical need [2][6] Price Target Adjustments - BofA raised its price target for United Therapeutics from $569 to $626, maintaining a Neutral rating, citing Tyvaso's potential as both a monotherapy and adjunct therapy for IPF [3][4] - Wells Fargo increased its target from $486 to $575, keeping an Equal Weight rating, and assigned a 95% probability of success for IPF approval, reflecting confidence in the TETON-1 data [3][5] Financial Performance - Tyvaso DPI generated $338.6 million in Q4 2025, marking a 24% year-over-year increase, solidifying its role as the primary growth driver for United Therapeutics [6] - The company's full-year 2025 EPS was reported at $27.86, exceeding estimates, with annual revenue reaching $3,182.7 million [9] Market Reaction - The stock closed at $588.36 on March 30, already above Wells Fargo's revised target and nearing BofA's new target, with a year-to-date gain of 20.75% and a one-year return of 91.67% [8] - The consensus analyst target stands at $605.75, supported by 9 Buy ratings and 4 Hold ratings across the coverage universe [8] Future Catalysts - The next significant catalyst for United Therapeutics is the ADVANCE OUTCOMES readout and targeted FDA submission in H2 2026 for ralinepag in PAH, which could further enhance the company's growth narrative [9]

Core Insights - Agomab Therapeutics has received U.S. Patent No. 12,577,230 for AGMB-447, an investigational inhaled small molecule inhibitor targeting ALK5 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) [1][2] - The patent provides intellectual property protection for AGMB-447 in the U.S. until at least 2041, excluding potential extensions [1] - AGMB-447 is designed to inhibit fibrosis specifically in the lungs while minimizing systemic exposure, aiming to offer a novel therapeutic option for IPF patients [3] Company Overview - Agomab is a clinical-stage biopharmaceutical company focused on developing therapies for fibro-inflammatory diseases with significant unmet medical needs [4] - The company aims to create organ-restricted therapies that enhance efficacy and reduce safety liabilities, with a mission to improve the quality of life for patients suffering from these disorders [4]